The MHRA has approved various GLP-1 agonists for specific indications, with NICE providing guidance on their use in type 2 diabetes (NG28) and weight management (TA875 for semaglutide/Wegovy, TA664 for liraglutide/Saxenda)
Dados toxicolgicos pr-clnicos: Os estudos de toxicidade aguda e subaguda em ratos no evidenciaram mortalidade nem toxicidade orgnica significativa, mesmo em doses amplamente superiores s doses teraputicas (at 100 vezes a dose eficaz)
But that doesnt mean [archived link] its guaranteed to happen or that you have to take a GLP-1 RA forever
Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG , Hofstetter WL, Maru DM, Skinner HD, Ajani JA
Diabetic patients are also at extreme risk because the disease frequently damages the autonomic nervous system, which destroys the bodys natural ability to automatically balance and regulate blood pressure
